Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Papaioannou

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
Nature Communications|September 15, 2021
Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myelomaJaime Alvarez-Benayas, Nikolaos Trasanidis, Alexia Katsarou, et al.
Blood|November 22, 2012
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myelomaAristeidis Chaidos, Chris P Barnes, Gillian Cowan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2015
The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Eleftheria Lamprianidou, Theodoros P Vassilakopoulos, et al.
European Journal of Haematology|July 5, 2017
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapiesFlora Zagouri, Efstathios Kastritis, Athanasios Zomas, et al.
Leukemia & Lymphoma|November 15, 2018
Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification systemPanagiotis T Diamantopoulos, Ioannis Kotsianidis, Argiris Symeonidis, et al.
Scientific Reports|November 18, 2024
biobank.cy: the Biobank of Cyprus past, present and futureEleni M Loizidou, Maria Kyratzi, Maria A Tsiarli, et al.
Biorxiv : the Preprint Server for Biology|August 14, 2023
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitorsRomanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2019
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine RegistryPanagiotis T Diamantopoulos, Vasiliki Pappa, Argiris Symeonidis, et al.
Hematological Oncology|June 5, 2020
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromesVasileios Papadopoulos, Panagiotis T Diamantopoulos, Sotirios G Papageorgiou, et al.
British Journal of Haematology|May 6, 2025
Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patientsAnthi Bouchla, Sotirios G Papageorgiou, Ioannis Kotsianidis, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
Nature Communications|September 15, 2021
Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myelomaJaime Alvarez-Benayas, Nikolaos Trasanidis, Alexia Katsarou, et al.
Blood|November 22, 2012
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myelomaAristeidis Chaidos, Chris P Barnes, Gillian Cowan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2015
The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Eleftheria Lamprianidou, Theodoros P Vassilakopoulos, et al.
European Journal of Haematology|July 5, 2017
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapiesFlora Zagouri, Efstathios Kastritis, Athanasios Zomas, et al.
Leukemia & Lymphoma|November 15, 2018
Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification systemPanagiotis T Diamantopoulos, Ioannis Kotsianidis, Argiris Symeonidis, et al.
Scientific Reports|November 18, 2024
biobank.cy: the Biobank of Cyprus past, present and futureEleni M Loizidou, Maria Kyratzi, Maria A Tsiarli, et al.
Biorxiv : the Preprint Server for Biology|August 14, 2023
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitorsRomanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2019
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine RegistryPanagiotis T Diamantopoulos, Vasiliki Pappa, Argiris Symeonidis, et al.
Hematological Oncology|June 5, 2020
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromesVasileios Papadopoulos, Panagiotis T Diamantopoulos, Sotirios G Papageorgiou, et al.
British Journal of Haematology|May 6, 2025
Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patientsAnthi Bouchla, Sotirios G Papageorgiou, Ioannis Kotsianidis, et al.
Pageof 15